Tesamorelin

Tesamorelin (10mg) — Stabilised GHRH Analogue Research Peptide

Tesamorelin (10mg) is supplied in Australia by Omega Peptides Australia from domestic stock, with same-day dispatch on orders placed before 12pm and an independent certificate of analysis for every batch. Commonly written as tesamorelin peptide, tesa peptide, tesamoralin, tesamorlin, tesamorilin, GHRH analogue or GHRH analog, it is a stabilised growth hormone-releasing hormone analogue studied for visceral adipose tissue and the GH/IGF-1 axis.

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH). It contains the full 44-amino-acid sequence of native GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine, a modification that protects the peptide from cleavage by dipeptidyl peptidase-IV and makes it more stable and more potent than the natural hormone. It was developed by the Canadian company Theratechnologies under the code TH9507 and is the active ingredient of the prescription medicine Egrifta. It is written as tesamorelin peptide and the misspelling tesamoralin is common.

Tesamorelin is studied for the regulation of visceral adipose tissue, for the growth hormone and IGF-1 axis, and for comparative pharmacology against shorter GHRH analogues such as sermorelin and Modified GRF (1-29). It binds the GHRH receptor on pituitary somatotroph cells and raises cyclic AMP, which stimulates the synthesis and pulsatile release of growth hormone; growth hormone then drives IGF-1 production in the liver and promotes lipolysis in adipose tissue, which is the pathway behind its effect on abdominal fat in clinical studies.

Omega Peptides Australia supplies tesamorelin as a high-purity (≥99% HPLC) COA-verified lyophilised powder in a 10mg vial, dispatched same day from within Australia on orders placed before 12pm. Every batch is independently tested and the certificate for your vial can be reviewed in our COA library before you order.

Key research areas

• Visceral adipose tissue research Tesamorelin is the best-characterised GHRH analogue in this field. Its Phase 3 clinical programme in HIV-associated lipodystrophy measured reductions in visceral abdominal fat by CT imaging and led to FDA approval in 2010, and the compound remains a reference for studying how growth hormone signalling alters fat distribution.
• Liver fat and metabolic research Because visceral fat and hepatic fat are closely linked, tesamorelin has been examined in clinical and preclinical models of liver fat accumulation and the associated metabolic changes, including effects on triglycerides and markers of liver injury.
• Growth hormone and IGF-1 axis research As a full-length GHRH analogue that preserves the natural pulsatile pattern, tesamorelin is used to study physiological growth hormone secretion, IGF-1 responses and the feedback loops that regulate the axis, without the continuous stimulation produced by albumin-bound analogues.
• Cognitive research Growth hormone and IGF-1 influence brain metabolism, and tesamorelin has been examined in clinical research in older adults for its effects on cognitive test performance and on brain chemistry measured by spectroscopy.
• Peptide stabilisation research The trans-3-hexenoyl modification is a well-known example of N-terminal protection against DPP-IV. Tesamorelin is used as a model for studying how such modifications change enzymatic stability, receptor potency and half-life relative to the unmodified hormone.
• Comparative GHRH-analogue studies Researchers compare tesamorelin with sermorelin, Modified GRF (1-29) and CJC-1295 DAC to examine how sequence length, stabilising substitutions and albumin binding affect duration and strength of the growth hormone response.

Tesamorelin in Australia

Tesamorelin is not registered on the Australian Register of Therapeutic Goods, so it is not stocked by Chemist Warehouse, Priceline or other pharmacies. In Australia it is supplied as a research-grade lyophilised vial by domestic research suppliers. Omega Peptides Australia holds Tesamorelin in stock within Australia and dispatches orders placed before 12pm the same business day on tracked domestic delivery, so material arrives in days rather than waiting on an international shipment and customs. Every batch is tested independently and its certificate is published in the COA library before the vial ships.

Researchers comparing GHRH-receptor and ghrelin-receptor pathways commonly run Tesamorelin alongside Ipamorelin or the CJC-1295 No DAC + Ipamorelin blend, both held in Australian stock.

How Tesamorelin works

Native GHRH is released from the hypothalamus in pulses and binds the GHRH receptor, a G-protein-coupled receptor on pituitary somatotrophs. Receptor activation stimulates adenylyl cyclase, raises intracellular cyclic AMP and switches on both the transcription of the growth hormone gene and the release of stored hormone. The problem with native GHRH as a research tool is that dipeptidyl peptidase-IV removes its first two residues within minutes, leaving an inactive fragment. Tesamorelin solves this by attaching a trans-3-hexenoic acid group to the N-terminal tyrosine, which blocks the enzyme's access to the cleavage site. The rest of the molecule is the complete 44-residue human sequence, so receptor recognition is unchanged and the peptide behaves like a longer-lived version of the natural hormone.

Even with this protection, tesamorelin has a short elimination half-life of roughly 26 to 38 minutes, which means it produces a physiological pulse of growth hormone rather than a sustained elevation. This distinguishes it from CJC-1295 DAC, whose albumin-binding linker extends activity to days, and places it closer to sermorelin, the unmodified GHRH(1-29) fragment, and to Modified GRF (1-29). Compared with those 29-residue analogues, tesamorelin retains the C-terminal portion of GHRH that the shorter peptides lack and carries a different form of protection, N-terminal acylation rather than amino-acid substitution, and it is the GHRH analogue that remains an approved medicine today.

Specifications

Available sizes and pricing

Tesamorelin is supplied in a single 10mg vial. It is a large peptide at about 5136 g/mol, so 10mg corresponds to roughly 1.9 micromoles, and its price reflects the cost of synthesising and purifying a 44-residue acylated sequence to 99% purity. Researchers comparing GHRH analogues can pair it with sermorelin at $89.99 for 5mg or with the CJC-1295 No DAC and Ipamorelin blend at $139.99.

• 10mg vial — $139.99 (about $14.00 per mg)

Quality and COA verification

Every batch of tesamorelin is independently tested by Janoshik Analytical. HPLC is used to confirm purity at or above 99% and mass spectrometry is used to confirm identity, which for tesamorelin means verifying the full 44-residue acylated sequence rather than a truncated GHRH fragment, since sermorelin and other shorter analogues are sometimes substituted for it. A Certificate of Analysis is issued for every batch and published in our COA library, so the result for the vial you receive can be checked against its batch number. The peptide is supplied as a lyophilised powder in a sealed sterile vial for stability in storage and transit, and each order is packed securely and discreetly for domestic delivery within Australia.

Frequently bought together

• Sermorelin (5mg) — $89.99, the unmodified GHRH(1-29) fragment for direct comparison of sequence length and stability
• CJC-1295 No DAC + Ipamorelin Blend (10mg) — $139.99, a substituted GHRH analogue paired with a ghrelin-receptor agonist for dual-pathway models
• Ipamorelin (10mg) — $89.99, a selective ghrelin-receptor agonist that complements GHRH-receptor stimulation
• Bacteriostatic Water (10mL) — $29.99, the recommended diluent for reconstituting lyophilised peptides

Research guides

• Tesamorelin research guide
• Sermorelin research guide
• CJC-1295 and Ipamorelin research guide
• How to store lyophilised peptides
• COA testing explained
• Peptide reconstitution calculator
• How to reconstitute peptides

Frequently asked questions

What is Tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone consisting of the full 44-amino-acid human GHRH sequence with a trans-3-hexenoyl group on its N-terminus. The modification protects it from enzymatic breakdown while preserving normal receptor binding. It was developed by Theratechnologies as TH9507 and is the active ingredient of Egrifta. Omega Peptides Australia supplies it as a COA-verified lyophilised powder in a 10mg vial for in-vitro laboratory research only.

What is Tesamorelin also known as?
It is also written as tesamorelin peptide, shortened to tesa peptide or tesamo, commonly misspelled tesamoralin, tesamorlin, tesamorilin, tesamoreline or tesamorellin, and it appears in the development literature as TH9507. Egrifta is the pharmaceutical brand name for the approved medicine, which is a different, finished product. The CAS number of the free peptide is 218949-48-5, and the acetate salt used by some suppliers has a separate CAS number. All of these names refer to the same 44-residue acylated GHRH analogue.

How does Tesamorelin work?
Tesamorelin binds the GHRH receptor on pituitary somatotrophs, raising cyclic AMP and stimulating both the synthesis and pulsatile release of growth hormone, which in turn increases hepatic IGF-1 and promotes lipolysis in adipose tissue. The trans-3-hexenoyl group on its N-terminal tyrosine blocks cleavage by dipeptidyl peptidase-IV, so it survives longer than native GHRH, although its half-life of roughly 26 to 38 minutes still produces a pulse rather than a sustained signal.

What does the research show about Tesamorelin?
Tesamorelin has the most complete clinical record of any GHRH analogue. Its Phase 3 programme in HIV-associated lipodystrophy reported reductions in visceral abdominal fat measured by CT and led to FDA approval in 2010. Later clinical research examined liver fat and metabolic markers, and separate studies in older adults looked at cognitive measures. Preclinical work continues to use it as a reference compound for GHRH-receptor pharmacology and for the growth hormone and IGF-1 axis.

Can I buy Tesamorelin at Chemist Warehouse or a pharmacy in Australia?
No. The pharmaceutical form of tesamorelin, Egrifta, is a prescription-only medicine in the countries where it is approved, such as the United States, and it is not stocked by Chemist Warehouse, Priceline or other Australian retail pharmacies. The material supplied here is a research-grade lyophilised compound with an independent batch Certificate of Analysis, intended for laboratory use, and it is not a pharmacy product.

Can Australian compounding pharmacies supply Tesamorelin?
Tesamorelin has been offered by some Australian compounding pharmacies on prescription. Compounding is only permitted for an individual patient on a valid prescription from a registered prescriber, within Pharmacy Board and TGA rules, and the TGA has stepped up compliance action on unapproved peptide products. Omega Peptides Australia is not a pharmacy. We supply the lyophilised research compound with a batch COA for in-vitro laboratory work only.

How do you reconstitute Tesamorelin?
Use bacteriostatic water. Let the vial reach room temperature, then add the water slowly down the inside wall so it runs onto the powder without splashing. Swirl gently until dissolved, do not shake. As a large acylated peptide, tesamorelin can take a little longer to dissolve than small peptides, so allow the vial a few extra minutes and swirl again if needed. Refrigerate at 2 to 8°C and use within 28 days.

How should Tesamorelin be stored?
Keep sealed lyophilised vials at 2 to 8°C for short-term storage or at minus 20°C for long-term storage, protected from light and moisture, and avoid repeated freeze-thaw cycles. The dry powder is stable for extended periods under these conditions. After reconstitution, store the solution in the refrigerator at 2 to 8°C and use within 28 days.

Where can I buy Tesamorelin in Australia?
Tesamorelin can be ordered directly from Omega Peptides Australia. Stock is held domestically, orders placed before 12pm are dispatched the same day with tracked shipping, and every batch has an independent Janoshik COA available in our library. Other GHRH analogues and secretagogues for comparative work are listed in our range of research peptides in Australia.

What does Tesamorelin cost in Australia?
Tesamorelin is $139.99 for a 10mg vial, which works out at about $14.00 per mg. The price reflects the synthesis of a 44-residue acylated peptide to 99% purity with independent testing. For comparative GHRH-analogue work, sermorelin is $89.99 for 5mg, CJC-1295 DAC is $89.99 for 5mg and the CJC-1295 No DAC and Ipamorelin blend is $139.99 for 10mg.

How do I get Tesamorelin online in Australia?
Select the 10mg vial on this page, add it to your cart and complete checkout. Orders ship from our Australian stock with tracked domestic delivery in discreet packaging, and orders placed before 12pm on a business day are dispatched the same day. Because the product ships from within Australia there is no customs clearance or import paperwork and delivery times are short.

Is Tesamorelin legal in Australia?
Omega Peptides Australia supplies tesamorelin strictly for lawful in-vitro laboratory research. It is not approved by the TGA for human or veterinary use and is not sold as a medicine or supplement. Purchasers are responsible for ensuring their intended use complies with all applicable laws.

How does Tesamorelin differ from Sermorelin and CJC-1295?
All three are GHRH-receptor agonists. Sermorelin is the unmodified first 29 residues of GHRH and is broken down quickly. CJC-1295 DAC is a substituted 29-residue analogue with an albumin-binding linker that extends its activity to days. Tesamorelin is the full 44-residue sequence protected by an N-terminal hexenoyl group, giving it more stability than sermorelin while keeping a short, pulsatile action, and it is the only one of the three currently marketed as an approved medicine, since sermorelin's earlier pharmaceutical product was withdrawn from the market.

Is Tesamorelin available in Australia?
Yes, as a research-grade lyophilised peptide from domestic suppliers. It is not a registered medicine in Australia and is not dispensed by pharmacies. Omega Peptides Australia holds Tesamorelin 10mg in Australian stock with same-day dispatch before 12pm.

Can you get Tesamorelin in Australia?
Yes, from an Australian research peptide supplier with domestic stock and a published COA per batch. Omega Peptides Australia dispatches Tesamorelin from within Australia on tracked delivery.

⚠ For in-vitro research and laboratory use only. Not for human or veterinary use.